|
May 2
|
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 2
|
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
|
|
May 2
|
Novocure Reports First Quarter 2024 Financial Results
|
|
Apr 25
|
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Apr 24
|
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
|
|
Apr 5
|
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
|
|
Apr 1
|
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
|
|
Apr 1
|
Novocure to Report First Quarter 2024 Financial Results
|
|
Mar 30
|
Why NovoCure Stock Soared 18.3% This Week
|
|
Mar 28
|
Why Novocure Stock Is Jumping Today
|
|
Mar 28
|
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?
|
|
Mar 27
|
Novocure Surges 12% On Brain Tumors Study; But Some Analysts Are Bearish
|
|
Mar 27
|
UPDATE 1-Novocure's lung cancer therapy succeeds in late-stage trial
|
|
Mar 27
|
Novocure's device shown to slow cancer progression in the brain in trial
|
|
Mar 27
|
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
|
|
Mar 13
|
Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?
|
|
Mar 11
|
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
|
|
Jan 11
|
Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know
|
|
Jan 11
|
GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?
|
|
Jan 9
|
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
|